Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids : Effect of drug, dose, and device
(2016) In Respiratory Medicine 120. p.54-63- Abstract
Background and aims Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device. Methods We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database. We assessed oral thrush incidence in patients initiating long-acting bronchodilators or FDC ICS/LABA therapy. We then compared different combination therapies (budesonide/formoterol fumarate dihydrate [BUD/FOR] and fluticasone... (More)
Background and aims Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device. Methods We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database. We assessed oral thrush incidence in patients initiating long-acting bronchodilators or FDC ICS/LABA therapy. We then compared different combination therapies (budesonide/formoterol fumarate dihydrate [BUD/FOR] and fluticasone propionate/salmeterol xinafoate [FP/SAL]) and devices (DPI and pMDI). Results Patients prescribed FDC ICS/LABA had significantly greater odds of experiencing oral thrush than those prescribed long-acting bronchodilators alone (adjusted OR 2.18 [95% CI 1.84–2.59]). Significantly fewer patients prescribed BUD/FOR DPI developed oral thrush compared with FP/SAL DPI (OR 0.77 [0.63–0.94]) when allowing for differences in prescribed doses between the drugs. A significantly smaller proportion of patients developed oral thrush in the FP/SAL pMDI arm than in the FP/SAL DPI arm (OR 0.67 [0.55–0.82]). Additionally, in the FP/SAL cohort (both DPI and pMDI), increased risk of oral thrush was significantly associated with high ICS daily dose (OR 1.97 [1.22–3.17] vs low daily dose). Conclusions ICS use increases oral thrush incidence in COPD and this effect is dose-dependent for FP/SAL therapies. Of the therapies assessed, FP/SAL pMDI and BUD/FOR DPI may be more protective against oral thrush.
(Less)
- author
- organization
- publishing date
- 2016-11-01
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Chronic obstructive pulmonary disease, Dry powder inhaler, Inhaled corticosteroid, Oral candidiasis, Pressurised metered-dose inhaler, Spacer
- in
- Respiratory Medicine
- volume
- 120
- pages
- 10 pages
- publisher
- Elsevier
- external identifiers
-
- scopus:84990895456
- pmid:27817816
- wos:000388116100008
- ISSN
- 0954-6111
- DOI
- 10.1016/j.rmed.2016.09.015
- language
- English
- LU publication?
- yes
- id
- d1a334de-b5d1-4b63-a150-44026f9f88c6
- date added to LUP
- 2016-10-31 08:56:38
- date last changed
- 2024-06-14 16:36:23
@article{d1a334de-b5d1-4b63-a150-44026f9f88c6,
abstract = {{<p>Background and aims Little information is available on real-life occurrence of oral thrush in COPD patients treated with ICS. We investigated oral thrush incidence in COPD patients prescribed FDC ICS/LABA therapies and assessed whether it is modulated by the ICS type, dose, and delivery device. Methods We conducted a historical, observational, matched cohort study (one baseline year before and one outcome year after initiation of therapy) using data from the UK Optimum Patient Care Research Database. We assessed oral thrush incidence in patients initiating long-acting bronchodilators or FDC ICS/LABA therapy. We then compared different combination therapies (budesonide/formoterol fumarate dihydrate [BUD/FOR] and fluticasone propionate/salmeterol xinafoate [FP/SAL]) and devices (DPI and pMDI). Results Patients prescribed FDC ICS/LABA had significantly greater odds of experiencing oral thrush than those prescribed long-acting bronchodilators alone (adjusted OR 2.18 [95% CI 1.84–2.59]). Significantly fewer patients prescribed BUD/FOR DPI developed oral thrush compared with FP/SAL DPI (OR 0.77 [0.63–0.94]) when allowing for differences in prescribed doses between the drugs. A significantly smaller proportion of patients developed oral thrush in the FP/SAL pMDI arm than in the FP/SAL DPI arm (OR 0.67 [0.55–0.82]). Additionally, in the FP/SAL cohort (both DPI and pMDI), increased risk of oral thrush was significantly associated with high ICS daily dose (OR 1.97 [1.22–3.17] vs low daily dose). Conclusions ICS use increases oral thrush incidence in COPD and this effect is dose-dependent for FP/SAL therapies. Of the therapies assessed, FP/SAL pMDI and BUD/FOR DPI may be more protective against oral thrush.</p>}},
author = {{Dekhuijzen, P. N Richard and Batsiou, Maria and Bjermer, Leif and Bosnic-Anticevich, Sinthia and Chrystyn, Henry and Papi, Alberto and Rodríguez-Roisin, Roberto and Fletcher, Monica and Wood, Lucy and Cifra, Alessandra and Soriano, Joan B. and Price, David B.}},
issn = {{0954-6111}},
keywords = {{Chronic obstructive pulmonary disease; Dry powder inhaler; Inhaled corticosteroid; Oral candidiasis; Pressurised metered-dose inhaler; Spacer}},
language = {{eng}},
month = {{11}},
pages = {{54--63}},
publisher = {{Elsevier}},
series = {{Respiratory Medicine}},
title = {{Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids : Effect of drug, dose, and device}},
url = {{http://dx.doi.org/10.1016/j.rmed.2016.09.015}},
doi = {{10.1016/j.rmed.2016.09.015}},
volume = {{120}},
year = {{2016}},
}